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The E3 region of adenovirus codes for several membrane proteins, most of which are involved in immune
evasion and prevention of host cell apoptosis. We explored the topology and targeting mechanisms of E3-6.7K,
the most recently described member of this group, by using an in vitro translation system supplemented with
microsomes. Here, we present evidence that E3-6.7K, one of the smallest signal-anchor proteins known,
translocates across the membrane of the endoplasmic reticulum in a posttranslational, ribosome-independent,
yet ATP-dependent manner, reminiscent of the translocation of tail-anchored proteins. Our analysis also
demonstrated that E3-6.7K could achieve several distinct topological fates. In addition to the previously
postulated type III orientation (N-luminal/C-cytoplasmic, termed NtmE3-6.7K), we detected a tail-anchored
form adopting the opposite orientation (N-cytoplasmic/C-luminal, termed CtmE3-6.7K) as well as the possi-
bility of a fully translocated form (N and C termini are both translocated, termed NCE3-6.7K). Due to the
translocation of a positively charged domain, both the CtmE3-6.7K and NCE3-6.7K topologies of E3-6.7K
constitute exceptions to the “positive inside” rule. The NtmE3-6.7K and NCE3-6.7K are the first examples of
posttranslationally translocated proteins in higher eukaryotes that are not tail anchored. Distinct topological
forms were also found in transfected cells, as both N and C termini of E3-6.7K were detected on the
extracellular surface of transfected cells. The demonstration of unexpected topological forms and translocation
mechanisms for E3-6.7K defies conventional thinking about membrane protein topogenesis and advises that
both the mode of targeting and topology of signal-anchor proteins should be determined experimentally.
Group C adenovirus membrane proteins are encoded by the
E3 region, a cassette of genes involved in immune evasion (55).
More specifically, E3/10.4K, E3/14.5K (receptor internaliza-
tion and degradation  [RID] and RID, respectively) (1, 9,
43–45), E3/14.7K (16), and E3-6.7K (1, 35) prevent death re-
ceptor-induced apoptosis and release of inflammatory media-
tors from infected cells while E3/19K inhibits antigen presen-
tation by retaining the major histocompatibility class I complex
in the endoplasmic reticulum (ER) (23, 38).
It was recently shown that a subset of E3-6.7K is localized at
the plasma membrane, where it is required by the RID com-
plex in downregulating the surface levels of tumor necrosis
factor-related apoptosis-inducing ligand receptor 1 (TRAIL-
R1) and TRAIL-R2 (1). The requirement for E3-6.7K in RID-
mediated downregulation of TRAIL-R1 has been disputed by
others (45). Nevertheless, we showed that even in the absence
of other viral proteins, E3-6.7K maintains ER calcium ho-
meostasis, confers resistance to death receptor- and calcium
ionophore-induced apoptosis, and reduces the tumor necrosis
factor-induced release of arachidonic acid from transfected
cells (35).
E3-6.7K was previously described as a small membrane gly-
coprotein localized primarily in the ER (54). It was presumed
to be a type III glycoprotein because its only asparagine resi-
dues that are candidate acceptors for Asn-linked glycosylation
are found in the N-terminal region of the protein (53). It
contains a single hydrophobic stretch that initiates membrane
insertion and also acts as a transmembrane domain, hence,
acting as a signal-anchor (SA) sequence. Curiously, when E3-
6.7K was fused to its cocistronic partner, E3/19K, the fusion
protein was fully translocated across the membrane of the ER
and directed E3/19K to the membrane of the ER (53). This
indicates that the SA domain of E3-6.7K does not act as a
stop-transfer sequence.
SA-containing proteins can achieve either an N-cytoplasmic/
C-luminal orientation, as seen for type II proteins, or an N-
luminal/C-cytoplasmic orientation, as seen for type III trans-
membrane proteins (reviewed by Goder and Spiess [15]).
Statistically, the topology of SA-containing proteins is deter-
mined by the distribution of charged residues (49) or the net
charge difference between the regions of the polypeptide flank-
ing the transmembrane domain (17). The presence of posi-
tively charged residues in a flanking domain correlates with its
retention in the cytoplasm (this observation is also called the
positive inside rule) (49). One possible explanation is that
positive residues found in the cytoplasmic domain of these
proteins interact with the anionic phospholipids on the cyto-
plasmic face of the membrane (48). It has also been observed
that the length and hydrophobicity of the transmembrane do-
main also affects the orientation of SA proteins, with long
hydrophobic regions favoring the type III orientation (40, 50).
Glycosylation of luminal exposed domains can also influence
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the topology of proteins by arresting lumenal exposed glyco-
sylation acceptor sites in the ER (14). In the case of some SA
proteins, the topology was also determined by the folding state
of the regions flanking the transmembrane domain (7).
SA-containing proteins can use both co- and posttransla-
tional modes of targeting to the ER. This is to be contrasted
with the mode of targeting employed by proteins containing a
cleavable signal sequence such as secreted soluble and type I
(N-luminal/C-cytoplasmic oriented) proteins, where transloca-
tion occurs cotranslationally and requires the targeting mech-
anism of the signal receptor particle (SRP) (12, 13). Most SA
domain-containing proteins employ a cotranslational, SRP-
mediated targeting mechanism. This has been observed in such
type II proteins as the invariant chain protein (30) and the
transferrin receptor (58) and in type III proteins like synapto-
tagmin II (24). There are also examples, albeit very few in
higher eukaryotes, of proteins that are posttranslationally
translocated. In fact, the only such proteins have their SA
domains in close proximity to their C termini (tail anchored
[TA] proteins). TA proteins include synaptobrevin (26, 51),
cytochrome b5, bcl-2 (22), and the vaccinia virus H3L protein
(6). These proteins insert in the ER membrane posttransla-
tionally, in the absence of the SRP or the Sec61 complex, and
assume a type II topology.
The lack of an N-terminal cleavable signal sequence and the
short length of the protein (61 amino acids) suggest that E3-
6.7K may not be a good substrate for the SRP and may employ
an unusual mode of targeting across the membrane of the ER.
Its membrane topology and targeting are important in deter-
mining its mode of action as an antiapoptotic protein and may
shed some light on the targeting mechanisms and properties of
small and hydrophobic membrane proteins.
MATERIALS AND METHODS
Materials and reagents. The RiboMax large-scale RNA production system-T7
and the nuclease-treated rabbit reticulocyte lysate and RNasin were obtained
from Promega Corp. (Madison, Wis.). Tissue culture supplies such as Dulbecco
minimal essential medium, penicillin, streptomycin sulfate, and L-glutamine were
obtained from Invitrogen while fetal calf serum was obtained from VWR Can-
ada. Grade VI apyrase, [-S]ATP, tosylsulfonyl phenylalanyl chloromethyl
ketone (TPCK)-treated trypsin (TPCK-trypsin), proteinase K (ProtK), and phe-
nylmethylsulfonyl fluoride (PMSF) were obtained from Sigma. Peptide-N-glyco-
sidase F (PNGaseF) was obtained from Boehringer Mannheim, and puromycin
was obtained from Clontech. Microsomes from Raji cells were prepared as
previously described by Levy et al. (28). A polyclonal rabbit antiserum raised
against a peptide corresponding to residues 47 to 61 in the sequence of Ad2
E3-6.7K, referred to here as R47-61, was obtained as a generous gift from
W. S. M. Wold (St. Louis University, St. Louis, Mo.).
Production of N-terminal or C-terminal FLAG-tagged E3-6.7K. The E3 region
plasmid pBR-E3 containing the EcoRI D fragment of Ad2 was a gift from
W. S. M. Wold (St. Louis University). The E3-6.7K and the E3/19K coding
regions were isolated and subcloned in pGEM 3Zf() under the control of the
T7 promoter and with the E3 polyadenylation signal. E3-6.7K cDNA was sub-
cloned from pGEM 3Zf() into pcDNA3.1 (Invitrogen) in frame with sequences
encoding a FLAG tag at the 5 end to generate pFLAG-6.7K, a vector that
expresses E3-6.7K with a FLAG tag at the N terminus. E3-6.7K was amplified by
PCR from pFLAG-6.7K and subcloned into pIRES-hrGFP-1a (Stratagene) to
generate pGFP/6.7K-FLAG, a vector that cocistronically expresses E3-6.7K with
a FLAG tag at the C terminus and green fluorescent protein (GFP), allowing for
the identification of transfected cells.
Immunofluorescence staining. HeLa cells were transiently transfected with
pGFP, pGFP/6.7K-FLAG, or pFLAG-6.7K by using FuGENE 6 (Roche). Trans-
fected cells were fixed with 2% paraformaldehyde for 20 min and, where indi-
cated, permeabilized with 0.1% saponin in 2% bovine serum albumin (BSA) in
phosphate-buffered saline for 15 min. Nonpermeabilized cells were treated with
2% BSA for 15 min. Cells were then blocked with 2% BSA for 1 h and reacted
with 1:1,000-diluted M2 anti-FLAG primary antibody (Sigma) in 2% BSA for 30
min. After incubation, the cells were washed extensively with 2% BSA, incubated
with 1:1,000-diluted Alexa Fluor 568 goat anti-mouse secondary antibody (Mo-
lecular Probes) in 2% BSA for 30 min at room temperature in the dark, and
washed five times with 2% BSA. Cells were treated with SlowFade Antifade
(Molecular Probes) and analyzed by confocal microscopy using a Bio-Rad Ra-
diance Plus on an inverted Zeiss Axiovert with DIC optics and Lasersharp
software (Bio-Rad).
In vitro transcription and translation. Transcription of E3-6.7K and E3/19K
cDNA from the pGEM vector under the control of the T7 promoter was carried
out according to the manufacturer’s protocol by using the RiboMax large-scale
RNA production system-T7 (Promega Corp.). Translation was carried out for 60
min at 30°C using a nuclease-treated rabbit reticulocyte lysate system (Promega
Corp.) in the presence of 37 kBq of [L-35S]cysteine (Amersham)/l and contain-
ing 70% reticulocyte lysate, 79 mM potassium acetate, 0.5 mM magnesium
acetate, 1 U of RNasin/l, and 0.5 mM PMSF. Unless otherwise indicated,
translation was performed in the presence of 8 l of microsomes for every 50-l
reaction mixture.
Immunoprecipitation and SDS-PAGE electrophoretic analysis. Unless other-
wise indicated, the translation reaction mixture was diluted in 10 volumes of TNE
buffer (20 mM Tris [pH 7.4], 150 mM NaCl, and 5 mM EDTA) and centrifuged
for 10 min at 12,000  g. The microsomal pellet was solubilized in TNE buffer
supplemented with 1% Triton X-100 and 2 mM PMSF. Samples were precleared
overnight with protein A-Sepharose CL-4B and then immunoprecipitated from
the supernatant with R47-61 antiserum for 2 h at 4°C followed by purification of
immune complexes with protein A-Sepharose CL-4B for 2 h at 4°C. The immune
complex-bead slurry was washed three times in 1% Triton X-100 and TNE
buffer, and one last wash was done in TNE buffer without detergent. Protein
samples or bead slurries were boiled for 10 min in 1 sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) loading buffer (0.6 M Tris [pH
7.0], 3% [wt/vol] SDS, 10% [vol/vol] glycerol, 70 mM dithiothreitol, 0.01% Serva
blue G) followed by treatment with 5 l of 0.5 M iodoacetamide for 15 min. The
products were examined by Tricine-SDS-PAGE according to the method of
Schägger and von Jagow (41) with a 16.5% T, 3% C separating gel and a 10% T,
3% C spacer gel (where percent T represents the total concentration of both
monomers, acrylamide, and bisacrylamide and percent C represents the percent-
age of cross-linker bisacrylamide relative to the total concentration).
Posttranslational translocation assays. To assay posttranslational transloca-
tion, translation was performed in the absence of microsomes for 1 h. Various
amounts of cycloheximide (as indicated in Fig. 2) were added, and samples were
incubated at room temperature for 15 min, 8 l of microsomes was added, and
the mixture was incubated for an additional hour. Alternatively, translation
reaction mixtures were treated with 2 mM puromycin (final concentration) for 30
min at 30°C, and the polysomes were sedimented by centrifugation at 100,000
rpm in a Beckman tabletop ultracentrifuge with a TLA100.1 rotor. The super-
natant containing ribosome-free polypeptide chains was incubated with 8 l of
microsomes for an additional 30 min at 30°C. Where indicated, the supernatant
and the microsomes were pretreated for 15 min at 30°C with 1 mM [-S]ATP or
50 U of grade VI apyrase/ml prior to incubation with microsomes.
Alkaline extraction and alkaline flotation of microsomes. High-salt alkali
extraction was performed by diluting the microsome suspension at the end of the
translation-translocation reaction in 20 volumes of 0.1 M sodium carbonate, pH
11.5, followed by centrifugation and reextraction. Alkaline flotation experiments
were performed as described by Kida et al. (24). After posttranslational trans-
location assays were performed, one half of the total reaction mixture was diluted
in 10 volumes of TNE buffer and subjected to centrifugation for 10 min at 12,000
 g followed by resuspension in TNE buffer and recentrifugation. The washed
microsomal pellet was then lysed in TNE and 1% Triton X-100, immunopre-
cipitated with R47-61 antiserum, and examined by Tricine-SDS-PAGE (see Fig.
2B). The other half of the posttranslational translocation reaction mixture was
mixed with an equal volume of 0.2 M Na2CO3 and incubated for 30 min on ice.
The samples were then mixed with 2.5 M sucrose to result in a 1.8 M sucrose final
concentration, transferred to centrifugation tubes, and overlaid with an equal
volume of 1.25 M sucrose–0.1 M Na2CO3 and with a 0.25 M sucrose–0.1 M
Na2CO3 layer. The gradients were spun at 100,000 rpm for 90 min in a Beckman
tabletop ultracentrifuge with a TLA100.1 rotor. The upper layers of alkali-
treated membrane fractions (1.25 M and 0.25 M sucrose layers not including the
1.8 to 1.25 M interphase) were pooled and labeled M (membrane associated)
while the bottom layer (1.8 M sucrose) was labeled S (containing extracted
peripheral proteins and soluble proteins). The samples were diluted with lysis
buffer, TNE, and 1% Triton X-100, precleared overnight with protein A–Sepha-
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rose CL-4B, immunoprecipitated with R47-61 antiserum, and examined by
Tricine-SDS-PAGE (see Fig. 2C).
Protease protection assays. To assay the membrane topology, translation was
terminated with the addition of 100 g of cycloheximide/ml, and then the mi-
crosomes were pelleted at 18,000  g, washed in STKMM buffer (250 mM
sucrose, 50 mM TEA-HCl [pH 7.5], 50 mM potassium acetate, 2.2 mM magne-
sium acetate, 0.1% -mercaptoethanol), resuspended in STKMM buffer with 1
mM CaCl2, and allowed to stabilize for 10 min on ice. ProtK was added at a final
concentration of 300 g/ml in the presence or absence of 2% NP-40, and the
samples were incubated for 30 min on ice. Preactivated TPCK-trypsin (final
concentration, 750 g/ml) was added in the presence or absence of 2% NP-40,
and samples were incubated for 30 min at room temperature. PMSF was added
to a final concentration of 2 mM to stop digestion, and membranes were pelleted,
solubilized in TNE plus 1% Triton X-100 supplemented with 2 mM PMSF, and
immunoprecipitated. Alternatively, if the microsomes were separated from the
translation reaction mixture prior to protease digestion, the microsomal pellet
was simply boiled in SDS-PAGE sample buffer and examined by electrophoresis
(Fig. 3C).
RESULTS
E3-6.7K translocates posttranslationally across the mem-
brane of the ER. It has been previously postulated that E3-
6.7K may be posttranslationally translocated or posttransla-
tionally glycosylated (54). Sequence analysis of E3-6.7K with
the Kyte and Doolittle algorithm (27) predicts a single trans-
membrane, SA, domain between residues 19 and 39 in the
polypeptide chain (hydropathicity score greater than 2) (Fig.
1). Please note that all three possible Asn-linked glycosylation
sites are N terminal to the transmembrane domain while the
charged residues are all basic and C terminal (at physiologic
pH) (Fig. 1). The E3-6.7K protein is present in infected cells in
two forms, a high-mannose glycosylated 14-kDa form and an
unglycosylated 6- to 7-kDa form (54). We noticed the appear-
ance of both of the previously observed forms of E3-6.7K in
microsomes following in vitro translation of E3-6.7K mRNA
(Fig. 2).
To investigate whether E3-6.7K is posttranslationally trans-
located across the ER membrane, we used cycloheximide to
block protein synthesis following the in vitro translation reac-
tion. We assayed translocation in the absence of translation by
adding microsomes after translation was stopped. The appear-
ance of the higher molecular mass glycosylated E3-6.7K of 14
kDa was used to establish the success of the translocation
reaction. We observed that the E3-6.7K protein can translo-
cate across the membrane of the ER in the absence of protein
synthesis (Fig. 2A, lanes 2 and 3) as efficiently as when trans-
lation is not inhibited (Fig. 2A, lane 4). As observed in Fig. 2A,
the lowest concentration of cycloheximide used was sufficient
to block protein synthesis when added at the beginning of the
translation reaction (Fig. 2A, lane 1).
We assayed whether bound ribosomes or ATP influence
E3-6.7K’s translocation across microsomal membranes. As a
reporter for complete translocation we relied on the acquisi-
tion of Asn-linked glycosylation, carried out by enzymes inside
the ER lumen (microsomal lumen). Several studies have em-
ployed Asn-linked glycosylation in combination with apyrase
treatment to establish the energy requirements for an in vitro
translocation reaction (21, 47, 56). This is because microsomes
contain preassembled oligosaccharyl-dolichol donor molecules
and the transfer of Glc3Man9GlcNAc2 onto polypeptides en-
tering the ER is not ATP dependent. In this study, we released
the nascent chains from polysomes by using puromycin and
then we sedimented the polysomes by high-speed centrifuga-
tion. The polysome-free supernatant was then tested for its
ability to support translocation of E3-6.7K in the presence or
absence of apyrase or nonhydrolyzable ATP. We found that
newly synthesized E3-6.7K chains were in a translocation-com-
petent state in the absence of bound ribosomes (Fig. 2B, lane
1 versus lanes 2 and 3). We also analyzed the energy require-
FIG. 1. Sequence analysis of E3-6.7K. A Kyte-Doolittle hydropathy plot of E3-6.7K displays the highly hydrophobic character of this protein.
The three predicted Asn-linked glycosylation sites are marked with white triangles (‚). Trypsin targets the peptide bond on the carboxyl side of
arginine and lysine residues, and is indicated on the figure as filled triangles (Œ). Residues 47 to 61 corresponding to the peptide epitope used to
raise the R47-61 rabbit polyclonal antisera are italicized and have an outside border. The positively charged residues are shown in bold.
456 MOISE ET AL. J. VIROL.









ments for the translocation of E3-6.7K. Before the transloca-
tion reaction occurred, the nascent chain and microsomes were
depleted of ATP through apyrase treatment or were treated
with a nonhydrolyzable ATP analogue ([-S]ATP). The results
demonstrate that the translocation across the membrane into
the lumen of the ER, accompanied by Asn-linked glycosylation
and the appearance of the 14kDa form was dependent on
ATP. Conversely, association of the 6.7-kDa nonglycosylated
form of E3-6.7K with the membranes appeared to be ATP
independent (Fig. 2B, lanes 4 and 5).
In the absence of Asn-linked glycans, it is difficult to say
whether the 6.7-kDa unglycosylated form of the protein was
peripherally or integrally associated with membranes following
ATP depletion or whether it simply precipitated onto mem-
branes in the absence of ATP. Therefore, it was necessary to
subject the microsomes and embedded proteins to alkaline
extraction and flotation gradient analysis, which is effective in
removing peripheral membrane proteins (24). We observed
that a large proportion of nascent chains failed to associate
with microsomes (Fig. 2C, 6.7-kDa band in odd-numbered
lanes). Even in the absence of ATP, some of the nascent chains
were still able to associate in a stable fashion with the mem-
branes, giving rise to an unglycosylated integral membrane
protein of 6.7 kDa (Fig. 2C, lanes 8 and 10). The 14-kDa form
appeared in the membrane-associated fraction (M) as an inte-
gral membrane protein (Fig. 2C, lanes 2, 4, and 6) only in the
presence of hydrolyzable ATP (Fig. 2C, lanes 8 and 10 versus
lane 6). We observed that depletion of ATP through apyrase
treatment was far more effective in blocking the translocation
step than competition with the nonhydrolyzable ATP analogue
[-S]ATP (Fig. 2B, lane 5 versus 4, and C, lane 10 versus 8). As
a result, membrane-bound E3-6.7K can be observed, albeit in
decreased amounts, in Fig. 2C, lane 8. Soluble fractions also
contained slower-migrating radiolabeled proteins of 16, 24,
and 32 kDa, which could represent SDS-resistant multimers of
E3-6.7K (Fig. 2C, lane 1). Proteins complexes of 24 and 32 kDa
were also seen in the membrane fraction, possibly representing
membrane-integrated, higher-order structures of E3-6.7K.
Further studies will be necessary to establish the existence and
significance of such structures in vivo.
The data presented here suggest that E3-6.7K is capable of
translocating across the ER membrane following complete
synthesis. One reason for this could be that the lack of a signal
FIG. 2. E3-6.7K translocates posttranslationally. (A) In vitro-syn-
thesized E3-6.7K translocated across the membrane of the microsomes
whether microsomes were present during translation (lane 4) or
whether they were added after translation was stopped with 1 or 10
mM cycloheximide (lanes 2 and 3, respectively). Lane 1, E3-6.7K
mRNA was translated for 1 h in the presence of 1 mM cycloheximide
to indicate an effective translation block. All samples were immuno-
precipitated with R47-61 antiserum and analyzed by SDS-PAGE.
(B) Translation was carried out in the absence of microsomes, then the
samples were treated with 2 mM puromycin (lanes 3, 4, and 5) to
release the nascent chains, and then we sedimented the polysomes
(P/S) (lanes 2 to 5). The resulting pool of proteins was then exposed to
microsomes to assay translocation. The ribosome-free nascent chains
and the microsomes were treated with [-S]ATP or apyrase, lanes 4
and 5, respectively, prior to coincubation. After translocation, half of
the total reaction was pelleted and washed in TNE buffer and the
resulting microsomes were immunoprecipitated with R47-61 anti-
serum and examined by SDS-PAGE and fluorography. (C) The other
half of the translocation reaction mixture was extracted with 0.2 M
Na2CO3 and subjected to alkaline flotation (1.8, 1.25, and 0.25 M
sucrose steps in 0.1 M Na2CO3). The 1.8 M layer contained soluble
material (S), and the 1.25 and 0.25 M pooled fractions contained
floated membrane material (M). The M and S fractions were immu-
noprecipitated with R47-61 antiserum and examined by SDS-PAGE
and fluorography. The black arrows (Š) indicate the 14-kDa glycosy-
lated form of E3-6.7K, and the white arrows () indicate SDS-resistant
complexes of multimers of E3-6.7K. The positions of protein molecu-
lar mass markers are shown at the right side of the panels. , com-
pound present; , compound absent.
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sequence and the length of the E3-6.7K protein emerging from
the ribosome do not allow enough time for the nascent chain
to interact with the SRP. Additionally, we noticed that an
ATP-dependent factor is necessary for E3-6.7K’s translocation
but not for its association with membranes.
The E3-6.7K protein adopts various membrane topologies.
The charge distribution is such that all charged residues are
basic and are localized at the C terminus of the E3-6.7K pro-
tein (Fig. 1). Based on charged residue distribution and the
presence of Asn-linked carbohydrates at the N terminus of the
protein, it has been proposed that E3-6.7K is a type III protein
that has an N-luminal/C-cytoplasmic orientation (54). The SA
domain does not, however, act as a stop-transfer sequence
when E3-6.7K is fused to E3/19K, directing the fusion protein
to the membrane of the ER (53).
We investigated the topology of E3-6.7K by performing
translation in vitro in the presence of microsomes followed by
digestion of the exposed domain of the in vitro-synthesized and
membrane-translocated E3-6.7K with ProtK. We then immu-
noprecipitated the remaining fragment with the R47-61 anti-
serum, which recognizes a peptide corresponding to the se-
quence of residues 47 to 61 of the mature protein (54).
Analysis of the topology of E3-6.7K indicates that the 6.7- and
14-kDa forms of the protein adopted different conformations.
The molecular form of 6.7 kDa was not glycosylated and ap-
pears to be the primary translation product, as seen in Fig. 3A,
lane 1, in the absence of microsomes. Digestion of the mem-
brane-bound form of 6.7 kDa with ProtK resulted in the in-
creased mobility of the protected fragment (Fig. 3A, lane 5
versus 2, and B, lane 3 versus 1). The membrane-protected
fragment of the 6.7-kDa form contains the C terminus domain,
based on the fact that it was recognized by the R47-61 poly-
clonal antisera. Therefore, we propose that the 6.7-kDa form
adopts a type II topology (C-translocated, or CtmE3-6.7K) with
its N terminus in the cytoplasm, which precludes the glycosyl-
ation of the Asn acceptor sites.
Treatment of the 14-kDa form of the protein with PNGaseF
generated the 6.7-kDa polypeptide, demonstrating that the
higher molecular weight is Asn linked and glycosylated (Fig.
3A, lane 3). In contrast to the 6.7-kDa form, digestion of the
microsome-embedded 14-kDa form did not result in a similar
shift in electrophoretic mobility (Fig. 3A, lane 5 versus 2, and
B, lane 3 versus 1). Then, deglycosylation of the protected
fragment of 14 kDa generated a protein product indistinguish-
able in size from the primary translation product (6.7-kDa
FIG. 3. In vitro analysis of the topology adopted by E3-6.7K indi-
cates various membrane configurations. E3-6.7K mRNA was trans-
lated in the presence of microsomes to generate a radiolabeled mem-
brane-embedded protein, and then the microsomes were isolated,
protease treated, lysed, and immunoprecipitated with R47-61 antisera
(in panels A and B) or examined without further immunoprecipitation
by SDS-PAGE (in panel C). The positions of protein molecular mass
markers are shown at the right side of the panels. (A) Lane 1 shows the
primary translation product of E3-6.7K in the absence of microsomes.
The microsome-embedded protein is treated with 300 g of ProtK/ml
to identify the membrane-protected domains in lanes 4 and 5. Lanes 3
and 4 show the immunoprecipitated protein following treatment with
PNGaseF. (B) Microsomes containing newly synthesized protein were
subjected to either high-salt-alkali extraction at pH 11.5 (lane 2) or
ProtK digestion in the absence (lane 3) or presence (lane 4) of 2%
NP-40 detergent. (C) The protease digestion pattern of membrane-
embedded E3-6.7K is examined in comparison with the one of E3/19K,
a well-characterized type I protein. Membrane-embedded E3-6.7K or
E3/19K was treated with 300 g of ProtK/ml or 750 g of TPCK-
trypsin/ml in the presence or absence of 2% NP-40 detergent, as
indicated. After proteolysis, the samples were boiled in SDS-PAGE
loading buffer and examined by SDS-PAGE. , compound present; ,
compound absent.
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fragment) (Fig. 3A, lane 4 versus 1). This suggests that a subset
of the 14-kDa protein is completely protected from exog-
enously added protease, having both its N and C termini inside
the ER lumen (termed NCE3-6.7K). Besides the unaltered
change in the electrophoretic mobility of the 14-kDa fragment
in Fig. 3A and B, we provided additional arguments for the
existence of an NCE3-6.7K topology. By virtue of its glycosyl-
ation, we can place the N terminus of the protected fragment
of 14 kDa inside the lumen of the ER. We also know that the
C terminus is intact because the protected fragment can be
immunoprecipitated with the R47-61 C-terminally directed an-
tisera. Based on these facts, we propose that at least some of
the 14-kDa glycosylated chains of E3-6.7K are protected from
exogenously added ProtK while embedded in the membrane
and that both the N and C termini of these proteins are found
within the ER lumen. Both the 6.7- and 14-kDa forms of the
protein are not susceptible to a high-salt extraction of the
microsomes (Fig. 3B, lane 2).
We noticed that there was a noticeable decrease in the
intensity of the 14-kDa form following protease digestion (Fig.
3A, lane 5 versus 2, and B, lane 3 versus 1). This suggested that
only a subset of 14-kDa proteins assumes the NCE3-6.7K to-
pology and that the loss of signal may be due to a yet unac-
counted form of the protein. More specifically, the use of
R47-61 C-terminally directed antisera to immunoprecipitate
the protein precludes the purification of fragments whose C
termini were digested. Consequently, in the results depicted in
Fig. 3C, we examined all the membrane-protected proteolytic
fragments without further purification. Following translation,
the microsomes were treated with ProtK or TPCK-trypsin in
the presence or absence of detergent and then examined di-
rectly by SDS-PAGE. Following ProtK digestion, we observed
a novel 12-kDa proteolytic fragment from the 14-kDa form of
E3-6.7K, which we had not detected previously by immuno-
precipitation (Fig. 3C, lane 7 versus 6). The novel subset of
proteins of the 14-kDa protein accessible to exogenously added
ProtK were also digested by exogenous TPCK-trypsin (Fig. 3C,
lane 8 versus 6). Based on the sequence of E3-6.7K, the only
targets for trypsin (arginine and lysine residues) are found at
the C terminus of the protein (Fig. 1). Therefore, we conclude
that in addition to the NCE3-6.7K topology, some of the 14-
kDa glycosylated proteins have a type III topology, with an
N-lumenal/C-cytoplasmic orientation (N-translocated, or
NtmE3-6.7K). Predictably, the unglycosylated CtmE3-6.7K form
with a type II topology (C terminus inside the lumen) was not
susceptible to TPCK-trypsin while embedded in the membrane
(6.7-kDa polypeptides) (Fig. 3C, lanes 6 and 8 versus the fast-
er-migrating fragment in lane 10). We tested our protease
protection assay by using a protein of known topology, the type
I membrane protein Ad2 E3/19K. Both ProtK and TPCK-
trypsin cleaved the cytoplasmic domain of E3/19K in Fig. 3C,
lanes 2 and 3 versus lane 1.
Even in the presence of detergent, we observed that the core
of E3-6.7K exhibits some intrinsic resistance to ProtK (Fig. 3C,
lane 9). Protease resistance in the presence of detergent has
been observed in other proteins, such as prion protein (Prp),
and did not preclude studies of its membrane topology in vitro
by protease digestion of exposed hydrophilic domains (18).
There is good evidence that both the N and C termini of
E3-6.7K are susceptible to ProtK. For example, we observed
that the ProtK-resistant fragment detected in Fig. 3C, lane 4,
was not recognized by the R47-61 antiserum (Fig. 3B, lane 4),
meaning it does not include the C-terminal domain. We also
observed that the cytoplasmic domain of the unglycosylated
6.7-kDa form was sensitive to ProtK while embedded in the
membrane (Fig. 3A, lanes 4 and 5, and B, lane 3). Since we
were able to immunoprecipitate the remaining proteolytic
fragment with the R47-61 antiserum, we conclude that the
protected fragment retained the C terminus and that the di-
gested cytoplasmic domain contained the N terminus of the
protein and was digested by ProtK. This means that both the N
and C hydrophilic domains were susceptible to proteolytic di-
gestion and that the fragment exhibiting intrinsic resistance
was within the hydrophobic core of the protein and, as such, its
presence has no consequence on the conclusions derived from
the use of ProtK to digest hydrophilic cytoplasmic domains.
Both N and C termini of E3-6.7K are detectable at the cell
surface. We sought to confirm our observations based on in
vitro analysis with studies of the topology of E3-6.7K expressed
in cells. The majority of E3-6.7K is intracellular and exhibits
sensitivity to endoglycosidase H digestion, indicating that the
attached glycans are primarily the ER-specific high-mannose
type (54). However, in addition to the ER, there is a subset of
the E3-6.7K proteins which localize to the plasma membrane
of cells and associate with the adenovirus RID complex, spe-
cifically with RID (1). In the previous study, the authors made
use of an N-terminally vesicular stomatitis virus-tagged and an
N-terminally FLAG-tagged E3-6.7K to demonstrate that the N
terminus of the protein is accessible to exogenously added
tag-specific antibodies at the cell surface (1). Similarly, in the
present study, we use an N-terminally FLAG-tagged and C-
terminally FLAG-tagged E3-6.7K to directly study the topol-
ogy of E3-6.7K in transfected cells. The tagged E3-6.7K cDNA
was cloned into a pIRES-GFP vector (Stratagene), which al-
lows us to identify transfected cells by virtue of the presence of
the cocistronically expressed GFP. To exclude nonspecific
staining, we show that the anti-FLAG monoclonal antibody
does not stain cells transfected with the pGFP vector alone
(Fig. 4). We analyzed the staining pattern of transfected cells
in the presence or absence of saponin (as a control of the
plasma membrane integrity). In the presence of saponin, the
antibody labeled intracellular membrane compartments (Fig.
4). In contrast, in the absence of saponin, the staining was very
specific for the ectoplasmic domain of E3-6.7K (Fig. 4). We
demonstrate that for both the N and C termini of E3-6.7K, the
FLAG tags are accessible to exogenously added antibodies
(Fig. 4). This demonstrates that both N- and C-terminal do-
mains of E3-6.7K can translocate across the membrane and
give rise to proteins that are capable of transport to the cell
surface. This provides support for both NtmE3-6.7K and CtmE3-
6.7 but does not allow us to distinguish between the NCE3-6.7K
and the other two forms.
DISCUSSION
The NtmE3-6.7K and NCE3-6.7K form (demonstrated to oc-
cur in vitro in this study) are the first examples of non-TA
proteins which translocate across the membrane of the ER in
a posttranslational, ribosome-independent manner. A possible
scenario for the sequence of events could proceed as outlined
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in Fig. 5. The nascent polypeptide chain of E3-6.7K is released
from the ribosome complex and the nascent polypeptide-asso-
ciated complex (52), and it interacts with such chaperones as
the tailless complex polypeptide 1 ring complex (33) and heat
shock proteins 70 and 40 to prevent its folding and aggregation
(11, 25). Then an ATP-dependent process, possibly mediated
by lumenal BiP, assists the translocation of either the N ter-
minus or the C terminus towards the lumen of the ER, gen-
erating the NtmE3-6.7K and CtmE3-6.7K forms, respectively.
This mechanism operates through a chaperone-mediated trap-
ping of protein domains (the Brownian ratchet model) as they
emerge on the luminal side of the ER (32). Though we do not
have evidence that the generation of the CtmE3-6.7K form is
also ATP dependent, as the CtmE3-6.7K form is indistinguish-
able in size from the membrane-associated precursor, the
translocation of the similar TA proteins was shown to be ATP
dependent (25, 26). Based on our observations of in vitro-
synthesized E3-6.7K, a subset of either the NtmE3-6.7K or the
CtmE3-6.7K membrane forms or both can undergo a second
translocation event of the cytosolic domain to generate a fully
translocated NCE3-6.7K protein. Once in the oxidizing envi-
ronment of the ER lumen, the protein would fold, assisted by
chaperones, and allow the attachment of carbohydrate moi-
eties where these domains are accessible to the luminal com-
partment. The minimum distance between a functional N-
terminal glycosylation acceptor site and the luminal end of the
transmembrane domain is 14 to 15 residues (37), which sug-
gests that only the most N-proximal Asn residue can be glyco-
sylated out of the three potential sites. The sorting and trans-
port of TA proteins along the secretory pathway following
insertion in the ER is not well understood. Results from trans-
fected cells indicate that more than one topological form of
E3-6.7K can be transported to the plasma membrane; further
studies are necessary to verify the existence and describe the
targeting of each of the three different topological forms of
E3-6.7K in infected cells.
We conclude that the topologies proposed here for the SA-
containing protein E3-6.7K challenge the current models of
membrane protein conformation in several important ways. To
begin with, the fully translocated NCE3-6.7K form and the type
II CtmE3-6.7K form of E3-6.7K are exceptions to the positive
inside rule, since both forms of the protein have their positively
charged C termini in the ER lumen. In addition, there are very
few examples of proteins that can adopt more than one mem-
brane topology. These have been observed for the polytopic
proteins such as the channel ductin (8), P-glycoprotein (60),
aquaporin-1 (31), and some single-spanning proteins such as
prion protein (PrP) (57), microsomal epoxide hydrolase (61),
and recently, the Newcastle disease virus fusion protein F (34).
In addition to two membrane-embedded conformations, rep-
resented by a type I and a type II conformation (NtmPrP and
CtmPrP, respectively), there is also a fully translocated form of
PrP (secPrP), the precursor to the glycolphosphatidyl inositol-
anchored protein found at the surface of the cell (PrPC) (18).
Though PrP has a cleavable signal sequence, it appears to
alternate between the two modes of transport. PrP appears to
utilize its signal sequence to cotranslationally generate the
NtmPrP and secPrP forms and its transmembrane domain to
posttranslationally generate the CtmPrP form (21).
The generation of the various PrP protein forms was pro-
posed to be controlled by trans-acting factors (19). In vitro-
synthesized PrP can assume different membrane conforma-
tions depending on the composition of the added microsomes
(19). Interestingly, when we translated E3-6.7K mRNA in the
presence of commercially available canine pancreas micro-
somes, we observed that the glycosylated forms of E3-6.7K
were not successfully generated (results not shown). Canine
pancreas microsomal membranes have also been shown not to
support the different topologies of aquaporin-1 (31). We are
FIG. 5. Model of the mode of translocation of E3-6.7K. N and C
represent the N and C termini, respectively. The Asn-linked high-
mannose carbohydrate modification is shown at the N terminus of the
14-kDa form. The region recognized by the R47-61 rabbit polyclonal
antisera is at the C terminus of the protein.
FIG. 4. Detection of FLAG-tagged E3-6.7K on the surface of transfected cells. (A) C-terminal FLAG-tagged E3-6.7K. HeLa cells were
transfected with either pGFP vector or pGFP/6.7K-FLAG. GFP exhibits green fluorescence. Cells were costained with M2 anti-FLAG monoclonal
antibody and Alexa 568-conjugated anti-mouse secondary antibody (magenta). (B) N-terminal FLAG-tagged E3-6.7K. HeLa cells were transfected
with pFLAG-6.7K and were stained with M2 anti-FLAG (-FLAG) antibody and Alexa 568-conjugated anti-mouse secondary antibody (magenta).
Cells not treated with saponin (nonpermeabilized) show staining of the extracellular FLAG epitope while cells treated with saponin (permeabil-
ized) show staining of both extra- and intracellular FLAG epitope. , compound present; , compound absent.
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currently pursuing the nature of the trans-acting factors that
influence transmembrane protein topology.
As a protein coded by a human pathogen, E3-6.7K belongs
to a very small class of mammalian proteins that are posttrans-
lationally transported into the ER (the subject of a recent
review, see reference 2). The mechanisms of translocation for
synaptobrevin (26, 51), Cx26 connexin (59), and a fragment of
the glucose transporter (36) require ATP, whereas for prepro-
cecropin, insertion is both ATP and signal sequence dependent
(42). Insertion of the bcl-2 and cytochrome b (5) proteins was
shown to require specific residues located at the C terminus
(22). However, more recently, a second study reexamined the
translocation of cytochrome b (5), demonstrating that translo-
cation as measured by glycosylation was inhibited by apyrase
treatment (using a similar assay as described in our study). The
same study also demonstrated that sec61-deficient yeast strains
support the translocation of cytochrome b (5, 56). The eluci-
dation of the mechanism of translocation of TA proteins will
benefit greatly from the use of genetically defined microsomes
and from examining a variety of TA proteins in parallel assays.
Nevertheless, none of the posttranslationally targeted TA pro-
teins described to date can assume multiple membrane topol-
ogies as seen for E3-6.7K.
The variety of functions ascribed to TA proteins show that in
many cases the targeting of the protein is functionally relevant.
For example, t-SNARE protein Ufe1p (39), syntaxin 3 and 4
(4), and the recently described Slt1 (5) are involved in vesicular
traffic. The antiapoptotic protein bcl-2 can be posttranslation-
ally targeted to both the ER and the mitochondria (22), which
allows it to inhibit the apoptotic response in both subcellular
locations (62). Another TA protein, the herpesvirus Us9 pro-
tein (3), localizes to the trans-Golgi network and is necessary
for axonal localization and transport of viral membrane pro-
teins (46). E3-6.7K has been implicated in the downregulation
of TRAIL-R1 and -R2 by binding to RID (1) (though possi-
bly not required for TRAIL-R1 [45] downregulation). The
RID complex is thought to downregulate Fas (9), epidermal
growth factor receptor (20), and TRAIL receptors by inducing
their internalization and degradation in the endosomal/lysoso-
mal compartment (29). In a separate study, we showed that
E3-6.7K alone is sufficient to protect transfected cells against
death receptor and thapsigargin-induced apoptosis. In addi-
tion, we showed that E3-6.7K maintains calcium ion homeosta-
sis in response to thapsigargin. These effects are reminiscent of
the protective role conferred by bcl-2 against thapsigargin-
induced calcium flux and apoptosis. In this study, we show that
E3-6.7K also shares the topology (the CtmE3-6.7K form) and
mode of targeting of bcl-2. Further studies are necessary to
establish whether, like bcl-2 (10), E3-6.7K directly or indirectly
alters the permeability of ER, hence decreasing the ER cal-
cium stores. It will also be important to establish whether the
different topological forms of E3-6.7K are responsible for its
distinct functions such as the maintenance of calcium ho-
meostasis in the ER versus downregulation of TRAIL recep-
tors in cooperation with RID at the plasma membrane. We
believe that studies of the mechanisms by which E3-6.7K af-
fects the different death receptor and calcium-release pathways
will benefit from understanding the topology and targeting of
the various forms of E3-6.7K.
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